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Cytochrome P450 (CYP) enzymes comprise the major drug-
metabolizing enzyme system in humans. Genetic polymor-
phisms or environmental factors such as dietary components, 
toxins, or drugs can affect the activity of these enzymes and 
result in interindividual variations in drug concentrations. 
In addition to metabolizing enzymes, drug influx and efflux 
proteins such as P-glycoprotein (P-gp) are important sources 
of pharmacokinetic variability in drug response, as has been 
underlined recently.1 The pharmacokinetic variability and 
modifications in activities of CYP and/or P-gp can cause 
various pharmacological and toxicological consequences. It 
is therefore important to precisely and reliably evaluate their 
in vivo activity (phenotyping). A cocktail approach involving 
the administration of multiple CYP- or P-gp-specific probe 
drugs can be used to simultaneously assess the activities of 
these enzymes and the transporter. Many phenotyping cock-
tails have been developed and used over the past 2 decades.2–7 
The use of some of these cocktails is limited by the fact that a 
few probe drugs, such as mephenytoin6 and debrisoquine,2,6 
are no longer available in many countries. Another limitation 
is the use of therapeutic doses or insufficiently validated probes 
that might provoke side effects,8 especially if used in clinical 
practice in a more vulnerable population. This limitation may 
be overcome by the use of lower probe doses, but this alterna-
tive requires the development of sensitive analytical methods. 
Several currently available phenotyping procedures require 
tedious and multiple venous blood sampling.2,4 For a few cock-
tails, limited sampling strategies and phenotyping indexes have 
been proposed, but these cocktails require the collection of 
both plasma and urine samples.3,5,6 Moreover, phenotyping 
indexes are established based on normal CYP function, and it 
is often unknown whether the chosen indexes will be reliable 
in case of altered CYP activity.
A novel and promising approach for CYP and P-gp activity 
phenotyping is the use of dried blood spots (DBSs) as a sam-
pling procedure. This sampling method has been successfully 
applied for therapeutic drug monitoring and in pharmacokinetic 
 studies.9–11 Recent studies have shown that DBS sampling could 
also be used for individual cytochrome phenotyping of CYP2C9 
(ref. 12) or CYP3A13 activities.
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The suitability of the capillary dried blood spot (DBS) sampling method was assessed for simultaneous phenotyping of 
cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp) using a cocktail approach. Ten volunteers received an oral 
cocktail capsule containing low doses of the probes bupropion (CYP2B6), flurbiprofen (CYP2C9), omeprazole (CYP2C19), 
dextromethorphan (CYP2D6), midazolam (CYP3A), and fexofenadine (P-gp) with coffee/Coke (CYP1A2) on four occasions. 
They received the cocktail alone (session 1), and with the CYP inhibitors fluvoxamine and voriconazole (session 2) and 
quinidine (session 3). In session 4, subjects received the cocktail after a 7-day pretreatment with the inducer rifampicin. 
The concentrations of probes/metabolites were determined in DBS and plasma using a single liquid chromatography–
tandem mass spectrometry method. The pharmacokinetic profiles of the drugs were comparable in DBS and plasma. 
Important modulation of CYP and P-gp activities was observed in the presence of inhibitors and the inducer. Minimally 
invasive one- and three-point (at 2, 3, and 6 h) DBS-sampling methods were found to reliably reflect CYP and P-gp 
activities at each session.
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The purpose of this study was to evaluate the usefulness and 
effectiveness of DBS sampling for simultaneous assessment of 
the activities of six CYP isoforms and P-gp using a low-dose phe-
notyping cocktail composed of caffeine (CYP1A2), bupropion 
(CYP2B6), flurbiprofen (CYP2C9), omeprazole (CYP2C19), 
dextromethorphan (CYP2D6), midazolam (CYP3A), and 
fexofenadine (P-gp). The reliability of the method for the 
assessment of the modulation of CYP and P-gp activities was 
examined both by administration of the cocktail alone and in 
the presence of known CYP and P-gp inhibitors and an inducer.
RESULTS
Ten volunteers participated in the study and successfully com-
pleted the four study sessions. None of the subjects reported side 
effects after cocktail administration. However, four volunteers 
reported short-lasting troubled vision (a well-known and com-
mon adverse effect of voriconazole)14 immediately after admin-
istration of fluvoxamine and voriconazole at session 2.
Poor CYP2C9, CYP2C19, and CYP2D6 metabolizers were not 
included in the study (see Methods section). Three volunteers 
were identified as CYP2D6 intermediate metabolizers (IMs) 
(*5/*10; *5/*41; and *10/*41), and the results for these volun-
teers were analyzed as a separate group (lower dextrorphan/
dextromethorphan (dor/dem) area under the concentration–
time curve (AUC) ratio; P = 0.017). A trend toward increased 
CYP2C19 metabolism (as determined by a lower omeprazole 
AUC and a higher 5′-hydroxyomeprazole/omeprazole (OH-opz/
opz) AUC ratio) was noticed in five volunteers who were het-
erozygous carriers of CYP2C19*17, but this did not reach 
statistical significance (P = 0.06). The 4′-hydroxybupropion/
bupropion (OH-bup/bup) AUClast ratio tended to be lower in 
the two homozygous CYP2B6*6 carriers, but due to the small 
subject number, the difference was not statistically significant. 
Two volunteers were heterozygous CYP2C9*2 carriers, but flur-
biprofen pharmacokinetics in these subjects did not differ from 
those of homozygous CYP2C9*1 carriers. Fexofenadine pharma-
cokinetic data for three volunteers with the TT-TT haplotype for 
the transporter adenosine triphosphate–binding cassette (ABC) 
B1 G2677T and C3435T single-nucleotide polymorphisms did 
not differ from the data of other subjects.
Pharmacokinetic profiles of all the CYP-specific substrates 
and metabolites were comparable in DBS and plasma in terms 
of distribution and elimination (Figure 1). Caffeine AUCs for 
the four volunteers who received Coke were approximately four 
times lower than the AUCs of those who received coffee; how-
ever, the paraxanthine/caffeine AUC ratios were similar, and 
therefore these were analyzed together (Table 1). For flurbipro-
fen, midazolam, and omeprazole, maximum plasma concentra-
tion (Cmax) and AUC were proportionally lower in DBS than in 
plasma, with an approximate mean ratio of 0.6 corresponding to 
the dilution factor due to the presence of blood cells. Bupropion 
or dextromethorphan Cmax and AUC were higher in DBS in 
comparison with plasma, probably as a result of blood cell parti-
tioning (Figure 1 and Table 1). For fexofenadine, a similar phar-
macokinetic profile was observed in DBS and plasma, with no 
statistically significant differences between the two matrices in 
terms of half-lives or time to maximum concentration (Tmax) at 
each session, whereas Cmax and AUC values were slightly higher 
in plasma, with a blood to plasma ratio of ~0.9 (Figure 2 and 
Table 2).
As expected, fluvoxamine and voriconazole inhibited 
CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A activities, 
as shown by a significant increase in AUClast for the adminis-
tered probes and decrease of the AUClast ratios of metabolite/
probe. The mean decrease in the AUClast ratios in DBS was 81% 
for paraxanthine/caffeine (par/caf), 93% for OH-bup/bup, 33% 
for 4-hydroxyflurbiprofen/flurbiprofen (OH-flb/flb), 88% for 
OH-opz/opz, and 66% for 1-hydroxymidazolam/midazolam 
(OH-mdz/mdz). Quinidine strongly inhibited CYP2D6, as 
shown by a mean AUClast ratio decrease for dor/dem of 99% 
for extensive metabolizers and 93% for IMs. Coadministration 
of quinidine also resulted in a significant 2.8-fold increase in 
fexofenadine AUClast. The same magnitude of interaction 
was observed in plasma, for which, at the inhibition sessions, 
the decrease in AUClast ratio was 81% for par/caf, 93% for 
OH-bup/bup, 36% for OH-flb/flb, 86% for OH-opz/opz, 62% for 
OH-mdz/mdz, and 99% for dor/dem; in addition, fexofenadine 
AUClast increase was 2.7-fold.
Pretreatment with rifampicin increased the mean metabo-
lite/probe AUClast ratios. The magnitude of this increase was 
1.15- (nonsignificant), 4.82-, 1.30-, 3.29-, and 5.6-fold in 
DBS and 1.54-, 5.08-, 1.25-, 2.50-, and 5.3-fold in plasma for 
par/caf, OH-bup/bup, OH-flb/flb, OH-opz/opz, and OH-mdz/
mdz, respectively. Fexofenadine AUClast decreased by 45 and 
51% in DBS and plasma, respectively.
The DBS concentration ratios of metabolite/probe (meta-
bolic ratios (MRs)) at each sampling time point after oral 
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
 3 Modulation and interindividual variability in the activities of 
CYP and P-gp can lead to differences in drug concentrations. 
The in vivo activity of these enzymes and the transporter can 
be assessed using a cocktail approach.
WHAT QUESTION DID THIS STUDY ADDRESS?
 3 This study evaluated the usefulness of dried blood spot 
(DBS) sampling for the assessment of CYP and P-gp activity 
using a new low-dose phenotyping cocktail.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 3 The activities of six CYP isoforms and P-gp can be measured 
using a low-dose cocktail approach with simple and mini-
mally invasive capillary sampling. The degree of modulation 
of CYP and P-gp activity in the presence of inhibitors/induc-
ers can be reliably assessed using three-point DBS samples.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY 
AND THERAPEUTICS
 3 The use of a low-dose cocktail accompanied by a minimally 
invasive DBS sampling can be easily implemented for the 
evaluation of CYP and P-gp activities in a clinical setting and 
can be used as a tool for therapeutic individualization.
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Figure 1 Concentration–time profiles for CYP probe substrates (circles) and their metabolites (triangles) obtained in 10 µl of capillary DBS (dashed lines) and 
venous plasma samples (continuous lines) after oral administration of cocktail alone (left column), in the presence of inhibitor(s) (middle), or in the presence of 
an inducer (right) in 10 healthy volunteers. CYP1A2 profile is presented only for volunteers who received coffee (n = 6); CYP2D6 profiles are presented only for 
EMs and UMs (n = 7). Error bars represent SD. CYP, cytochrome P450; DBS, dried blood spot; EM, extensive metabolizer; UM, ultrarapid metabolizer.
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administration of the cocktail, alone and with pretreatment, are 
shown in Figure 3. Statistically significant differences among the 
sessions for every sampling point were observed for OH-bup/
bup, OH-flb/flb, and dor/dem MRs. OH-mdz/mdz MRs at the 
inhibition and induction sessions statistically differed from 
those of the cocktail-alone session at every sampling point for 
which the substances could be quantified (0.5–3 h). Most signifi-
cant statistical differences (P < 0.01) in OH-opz/opz MRs were 
observed 2, 3, and 4 h after cocktail administration. MRs of par/
caf significantly decreased at each time point for the inhibition 
session. At the induction session, a tendency toward an increase 
in MRs was observed, but the difference was statistically signifi-
cant (P < 0.05) only 4 h after cocktail administration.
The Spearman rank correlation coefficients (ρs) between the 
MRs at each time point and the AUClast ratios for each session 
are shown in Table 3. The MRs of par/caf (0.5–8 h), OH-bup/
bup (1–8 h), OH-flb/flb (2–8 h), and dor/dem (1–8 h) were 
highly correlated with their respective AUClast ratios at each 
separate session (ρs > 0.74; P < 0.015). The OH-mdz/mdz MRs 
at 0.5, 1, and 2 h of each session significantly correlated with 
the AUClast ratio (ρs > 0.64; P ≤ 0.043). For OH-opz/opz, the 
correlation was significant at 2, 3, and 4 h of the cocktail-alone 
session and at the inhibition session (ρs > 0.69; P ≤ 0.025), but 
no correlation was observed at the induction session.
Limited (three- or four-point) sampling strategy was 
 evaluated for P-gp activity assessment, and the best correlation 
(ρs ≥ 0.964; P < 0.001) for each session was observed between 
AUClast and AUC2,3,6 (Table 4). Limited AUC2,3,6 sampling 
perfectly predicted the magnitude of interactions, as shown by 
the mean 3.0-fold AUC2,3,6 (vs. 2.8-fold for AUClast) increase 
after quinidine administration and 48% AUC2,3,6 (vs. 45% for 
AUClast) decrease after rifampicin pretreatment in the DBS 
method (Table 2).
DISCUSSION
We evaluated the utility of DBS sampling for simultaneous 
assessment of P-gp and CYP function using a seven-drug phe-
notyping cocktail. All the currently available cocktails require 
venous blood sampling, often accompanied by urinary sampling. 
Although this seems acceptable for clinical research studies, a 
less invasive method, using, for instance, capillary blood after 
a small finger prick, would enhance the acceptance of pheno-
typing in a clinical setting. Because plasma is the historically 
accepted matrix for drug analysis, it is important to evaluate the 
correlation between drug concentrations in plasma and capil-
lary blood. We have previously shown that a great correlation 
Figure 2 Concentration–time profile of fexofenadine in capillary DBS (dashed 
lines) and venous plasma samples (continuous lines) after administration of 
the cocktail capsule alone (circles), with a P-gp inhibitor (squares), or with 
a P-gp inducer (triangles) in 10 healthy volunteers. Error bars represent SD. 
DBS, dried blood spot; P-gp, P-glycoprotein.
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Table 2 Pharmacokinetic parameters of P-gp probe drug fexofenadine after oral administration of cocktail with and without 
quinidine and rifampicin
Parameter
DBS Plasma
Cocktail 
alone
Cocktail + 
inhibitor
ratio 
(95% CI)
Cocktail + 
inducer
ratio 
(95% CI)
Cocktail 
alone
Cocktail + 
inhibitor
ratio 
(95% CI)
Cocktail + 
inducer
ratio 
(95% CI)
Cmax (ng/ml) 28.1 ± 15.0 79.4 ± 18.6 3.14  
(2.35–4.21)
14.4 ± 4.2 0.55  
(0.42–0.73)
34.4 ± 21.2 82.4 ± 19.5 2.75  
(1.84–4.12)
15.1 ± 4.7 0.49  
(0.35–0.69)
Tmax (h) 2.2 ± 0.8 2.4 ± 0.5 — 2.4 ± 0.7 — 2.5 ± 0.7 2.3 ± 0.5 — 2.8 ± 0.8 —
AUC8 (h·ng/ml) 118.5 ± 49.8 316.8 ± 64.5 2.84  
(2.15–3.75)
56.6 ± 15.1 0.50  
(0.38–0.65)
139.6 ± 68.0 343.7 ± 69.1 2.66  
(1.86–3.82)
59.2 ± 15.8 0.45  
(0.34–0.60)
AUC∞ (h·ng/ml) 145.2 ± 57.2 357.6 ± 71.8 2.69  
(1.94–3.73)
61.2 ± 15.2 0.44  
(0.33–0.60)
181.3 ± 78.0 388.2 ± 77.2 2.31  
(1.51–3.53)
62.7 ± 12.0 0.41  
(0.28–0.62)
AUC2,3,6 (h·ng/ml) 100.9 ± 47.5 285.5 ± 67.1 3.05  
(2.27–4.09)
50.4 ± 15.3 0.52  
(0.39–0.71)
117.7 ± 58.3 306.3 ± 64.7 2.82  
(2.00–3.99)
52.3 ± 15.1 0.47  
(0.34–0.65)
t1/2 (h) 2.6 ± 0.8 2.1 ± 0.3 — 1.8 ± 0.5 — 3.1 ± 1.5 2.1 ± 0.3 — 1.6 ± 0.1 —
Cl/F (L/h) 198.3 ± 81.3 72.5 ± 14.4 0.37  
(0.27–0.52)
435.4 ± 124.6 2.25  
(1.65–3.07)
161.3 ± 64.8 66.9 ± 14.4 0.43  
(0.28–0.66)
411.0 ± 72.5 2.42  
(1.62–3.62)
Data are presented as mean values ± SD and geometric mean ratios with 95% CIs.
AUC, area under the plasma concentration–time curve; CI, confidence interval; Cl/F, apparent clearance; Cmax, maximum plasma concentration; DBS, dried blood spot; 
P-gp, P-glycoprotein; t1/2, half-life; Tmax, time to maximum plasma concentration.
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existed between the plasma and DBS concentrations of all probe 
drugs and their metabolites (R2 = 0.843–0.985).15 As a result, the 
pharmacokinetic profiles observed in this study and the magni-
tude of modulation of CYP and P-gp activities in the presence 
of inhibitors or the inducer were similar in the two matrices 
(see Supplementary Figure S1 online for details).
To further enhance phenotyping acceptance and to minimize 
the potential pharmacodynamic effect of the probe drugs, the 
probe doses used in this cocktail were at least two times lower 
than the lowest commercialized doses. Probe and metabolite 
concentrations were assessed using a single analytical method 
after a minimal sample pretreatment,15 which represents a great 
advantage in terms of time and costs in comparison to previ-
ously published cocktails for which individual methods with 
complex sample preparation were used.3–5
The use of different matrices and the complicated sampling 
procedures are considered major drawbacks of many pheno-
typing cocktails. To overcome this limitation, several cocktails 
propose the use of single–time point plasma MRs or urinary 
MRs as phenotyping metrics. Although changes in metrics 
in the presence of inhibitors/inducers comprise one of the 
main validation criteria for phenotyping metrics, this ques-
tion has been rarely investigated in the previously proposed 
cocktails.16
Almost all of the previously published cocktails included 
caffeine as a probe drug to evaluate CYP1A2 activity. The par-
axanthine/caffeine ratio in plasma or urine is often used as a 
phenotyping index. Caffeine is only weakly bound to plasma 
proteins and enters into erythrocytes but does not bind to pro-
teins there.17 Therefore, its plasma concentrations were only 
slightly higher than the DBS concentrations, and the observed 
pharmacokinetic profiles were similar in the two matrices.
As expected,18,19 fluvoxamine potently inhibited CYP1A2 
activity, as shown by a decrease in the AUClast ratio of par/caf 
and the MRs at different sampling times in DBS. Rifampicin 
is known to be only a weak inducer of CYP1A2. The admin-
istration of rifampicin slightly, but not significantly, increased 
paraxanthine/caffeine AUClast ratio in DBS. These results are 
consistent with previously published data in which rifampicin 
increased the mean par/caf ratio 1.2- to 1.3-fold (4 h20 and 6 h21 
plasma samples, respectively). In the current study, 4- and 6-h 
DBS MRs increased by 1.25-fold. Ryu et al.3 have shown that an 
excellent correlation existed between the AUClast ratio and the 
single- point MRs in plasma. These results were confirmed for 
DBS samples in our study, which also showed that an important 
correlation existed between these parameters even when CYP 
activity was modulated. The best correlation was observed at 2 h 
(ρs ≥ 0.927; P < 0.001).
The CYP2B6 enzyme is involved in the metabolism of ~8% 
of clinically used drugs, including bupropion, efavirenz, metha-
done, propofol, cyclophosphamide, and tamoxifen.22 Despite 
its importance in drug metabolism, most previously published 
cocktails did not include a probe for assessment of CYP2B6 
activity. As suggested by individual CYP2B6-phenotyping stud-
ies23,24 and by the European Medicines Agency,25 bupropion was 
used as a probe drug in our cocktail. As expected, administra-
tion of voriconazole potently inhibited CYP2B6 and resulted in a 
1.3-fold increase in bupropion AUC, which is in agreement with 
a previously published study.26 Rifampicin-mediated induction 
led to an approximately threefold decrease in bupropion AUC, as 
Figure 3 Metabolic ratio profiles after oral administration of cocktail capsule alone (diamonds), with an inhibitor (squares), or with an inducer (triangles) in dried 
blood spots. *P < 0.05; **P < 0.01. dor/dem: continuous lines are used for extensive metabolizers (EMs) and dashed lines for intermediate metabolizers (IMs). 
bup, bupropion; caf, caffeine; dem, dextromethorphan; dor, dextrorphan; mdz, midazolam; OH-bup, 4-hydroxybupropion; OH-flb, 4-hydroxyflurbiprofen; flb, 
flurbiprofen; OH-mdz, 1-hydroxymidazolam; OH-opz, 5-hydroxyomeprazole; opz, omeprazole; par, paraxanthine.
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Table 3 Spearman rank correlations (ρs) between the AUClast ratios of metabolite/probe and the metabolic ratios in DBS at various 
time points at different sessions
CYP Phenotyping indexes Sampling time (h)
Cocktail alone Cocktail + inhibitor(s) Cocktail + inducer
ρs P value ρs P value ρs P value
1A2 [par]/[caf ] 0.5 0.964 <0.001 0.973 <0.001 0.860 0.001
1 0.960 <0.001 0.972 <0.001 0.927 <0.001
2 0.985 <0.001 0.982 <0.001 0.927 <0.001
3 0.988 <0.001 0.960 <0.001 0.900 <0.001
4 0.960 <0.001 0.963 <0.001 0.927 <0.001
6 0.815 0.004 0.979 <0.001 0.782 0.008
8 0.794 0.006 0.884 0.001 0.742 0.014
2B6 [OH-bup]/[bup] 1 0.964 <0.001 0.910 <0.001 0.952 <0.001
2 0.782 0.008 0.756 0.011 0.879 0.001
3 0.903 <0.001 0.827 0.003 0.927 <0.001
4 0.939 <0.001 0.930 <0.001 0.927 <0.001
6 0.842 0.002 0.952 <0.001 0.952 <0.001
8 0.745 0.013 0.869 0.001 0.830 0.003
2C9 [OH-flb]/[flb] 1 0.997 <0.001 0.402 0.249 0.927 <0.001
2 0.982 <0.001 0.778 0.008 0.903 <0.001
3 0.979 <0.001 0.939 <0.001 0.964 <0.001
4 0.976 <0.001 0.982 <0.001 0.921 <0.001
6 0.927 <0.001 1.000 <0.001 0.855 0.002
8 0.930 <0.001 0.915 <0.001 0.857 0.002
2C19 [OH-opz]/[opz] 2 0.809 0.005 0.869 0.001 0.285 0.425
3 0.806 0.005 0.867 0.001 0.479 0.162
4 0.697 0.025 0.888 0.001 0.418 0.229
6 0.612 0.060 0.891 0.001 0.750 0.052
8 0.511 0.132 0.924 <0.001 0.200 0.747
AUC
AUC
2 3 6
2 3 6
, ,
, ,
 OH-opz
 opz
2, 3, 6 0.855 0.002 0.964 <0.001 0.855 0.002
2D6 dor/dem 1 0.891 <0.001 0.745 0.013 — —
2 1.000 <0.001 0.948 <0.001 — —
3 1.000 <0.001 0.964 <0.001 — —
4 0.988 <0.001 0.979 <0.001 — —
6 0.976 <0.001 0.918 <0.001 — —
8 0.976 <0.001 0.821 0.023 — —
3A4 [OH-mdz]/[mdz] 0.5 0.830 0.003 0.862 0.001 0.697 0.025
1 0.915 <0.001 0.760 0.011 0.647 0.043
2 0.745 0.013 0.742 0.014 0.673 0.033
3 0.745 0.013 0.762 0.010 0.500 0.391
4 0.442 0.200 0.738 0.015 — —
6 0.895 0.001 0.911 <0.001 — —
Chosen phenotyping indexes are shown in bold.
AUClast, AUC from 0 to 8 h, except for mdz and OH-mdz at the induction session, when AUClast = AUC from 0 to 3 h.
AUC, area under the plasma concentration–time curve; bup, bupropion; caf, caffeine; CYP, cytochrome P450; DBS, dried blood spot; dem, dextromethorphan; dor, dextrorphan; 
mdz, midazolam; OH-bup, 4′-hydroxybupropion; OH-flb, 4′-hydroxyflurbiprofen; OH-mdz, 1′-hydroxymidazolam; OH-opz, 5′-hydroxyomeprazole; opz, omeprazole; par, 
paraxanthine.
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previously observed.23 The inhibition and induction were much 
more obvious when OH-bup/bup AUClast ratio or single-point 
MRs were used as phenotyping indexes (Table 1 and Figure 3). 
At each session, AUClast ratios most strongly correlated with 
DBS MRs at 4 h (ρs ≥ 0.927; P < 0.001), but important and sig-
nificant correlations were also observed at 1, 3, and 6 h.
Several drugs have been suggested as potentially useful probes 
for CYP2C9 phenotyping, including tolbutamide, phenytoin, 
warfarin, and losartan. To palliate the limitations of each of 
these drugs, flurbiprofen was recently validated as a reliable 
probe for CYP2C9 phenotyping.27 A previous study has dem-
onstrated the utility of DBS sampling for individual CYP2C9 
activity assessment.12 The pharmacokinetic profiles of flb and 
OH-flb in both DBS and plasma were similar to those observed 
in our study. Despite the use of different inhibitors (fluconazole 
vs. voriconazole + fluvoxamine), the magnitude of inhibition 
was comparable in the two studies. The magnitude of CYP2C9 
induction by rifampicin was in agreement with previously pub-
lished studies in which flurbiprofen12 or losartan20,28 was used 
as the probe drug.
Omeprazole is frequently used as a probe to assess CYP2C19 
activity. It is metabolized by both CYP3A and CYP2C19, with 
the transformation of omeprazole to 5-hydroxyomeprazole 
being predominantly mediated by CYP2C19. Omeprazole 
hydroxylation (opz/OH-opz) as a phenotyping index has been 
shown to correlate with the hydroxylation of S-mephenytoin and 
also reliably predicts CYP2C19 genotypes.29 Although in vitro 
studies indicate an inhibitory effect of omeprazole on CYP3A 
activity, previous cocktail studies have shown that omeprazole 
does not influence the pharmacokinetic parameters of mida-
zolam in vivo. An inhibitory effect of omeprazole on CYP2C19 
activity is suspected, but this is not expected to occur at a 5-mg 
dose. However, one should be aware of this risk if higher ome-
prazole doses are used for phenotyping.
Important modulation of CYP2C19 activity occurred in the 
presence of inhibitors (fluvoxamine and voriconazole) and an 
inducer (rifampicin), as seen by modification of OH-opz/opz 
AUC ratio. Previous studies have reported a similar extent of 
CYP2C19 induction by rifampicin (4.2- and 2.6-fold).20,28 These 
and other studies2,3 have used a single-point opz/OH-opz MR at 
3 or 4 h as a phenotyping index. Ryu et al.3 have shown a good 
correlation between the AUClast ratio and single-point MRs in 
plasma. In our study, good correlation between these parameters 
was observed in both plasma and DBS at both the cocktail-alone 
and inhibition sessions, but the correlation was nonsignificant at 
the induction session. Despite the lack of correlation, the 2-, 3-, 
and 4-h MRs at the induction session were significantly higher 
than those of the cocktail-alone session, indicating that induc-
tion of CYP2C19 activity could be predicted by a single-point 
MR. However, the use of limited-sample (2-, 3-, and 6-h) AUC 
ratios, which significantly correlate with AUClast ratios at every 
session (ρs ≥ 0.855, P ≤ 0.002), might constitute a better phe-
notyping index than the use of single-point MRs, especially if 
CYP2C19 induction is suspected.
In a review comparing several CYP2D6-phenotyping drugs, 
dextromethorphan and debrisoquine were considered the 
best probes, with debrisoquine having a very limited availabil-
ity.30 The urinary MR of dem/dor has been frequently used as 
a phenotyping index. This metric is sensitive to phenomena 
such as urinary pH changes and may therefore contribute to 
an increased variability, which can be overcome by the use of 
plasma AUC ratios. Moreover, AUC ratios showed a much bet-
ter correlation with dem oral clearance than did urinary MRs.31 
Excellent correlation between 3-h plasma MR and AUC ratios 
was previously reported.32 We have further confirmed a strong 
correlation with DBS MRs at 2, 3, or 4 h (ρs ≥ 0.948, P < 0.001), 
both when the enzymatic function was normal and when it was 
inhibited by quinidine. As expected, quinidine strongly and 
almost completely inhibited CYP2D6 function, as shown by 
decreases in AUC ratios and single-point MRs. In addition to 
the modulation in the presence of inhibitor, DBS single-point 
MR was able to reliably distinguish genotypic extensive metabo-
lizers from IMs(Figure 3). The MRs and AUC ratios in IMs 
were approximately eight times lower in comparison with those 
of extensive metabolizers at the cocktail-alone session. At the 
inhibition session, the production of dextromethorphan was 
also lower in IMs.
The majority of studies evaluating CYP3A activity have used 
midazolam as a probe drug. Many studies have evaluated the 
possibility of using limited-sampling methods with either 
single-point mdz concentration or single-point OH-mdz/mdz 
MRs.3,33,34 In this study, MRs from 0.5 to 2 h correlated with 
AUC ratios at every session. Voriconazole significantly inhibited 
CYP3A and lowered OH-mdz/mdz AUC ratio to 0.34-fold of the 
baseline AUC ratio. The inhibition was slightly lower than that 
reported in a previous study (0.26-fold reduction in AUC ratio) 
in which voriconazole was administered for 2 days (400 mg b.i.d. 
the first day and 200 mg b.i.d. the second day).35 The difference 
in dose and duration of voriconazole administration can explain 
the slight difference in the results. At the induction session, 
OH-mdz and mdz could be reliably quantified until 3 h after 
cocktail administration. Differences exist regarding the magni-
tude of CYP3A induction by rifampicin in previously published 
studies. A 3.3-fold increase in AUC ratio has been reported by 
Inui et al.,28 whereas Backman et al.36 found a 9.5-fold increase. 
The increase observed in the current study is between these two 
Table 4 Spearman rank correlations (ρs) between fexofenadine 
AUC0–8 and different three- or four-point fexofenadine AUCs in 
DBS at different sessions
Sampling points used for 
AuC determination (h)
Cocktail alone
Cocktail + 
inhibitor(s)
Cocktail + 
inducer
ρs P value ρs P value ρs P value
1, 2, 4 0.952 <0.001 0.685 0.029 0.842 0.002
2, 3, 4 0.976 <0.001 0.806 0.005 0.939 <0.001
2, 3, 6 0.976 <0.001 0.964 <0.001 0.964 <0.001
2, 4, 6 0.976 <0.001 0.915 <0.001 1.000 <0.001
1, 2, 4, 6 0.988 <0.001 0.939 <0.001 1.000 <0.001
Chosen limited-sampling AUC is shown in bold.
AUC, area under the plasma concentration–time curve; DBS, dried blood spot.
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values. The use of 1- or 2-h DBS MRs instead of AUC ratios 
resulted in the same interaction magnitude for both induction 
and inhibition.
Digoxin, which has a narrow therapeutic index, and fex-
ofenadine are the most commonly used and currently recom-
mended in vivo P-gp phenotyping probes. Whereas digoxin 
is mostly used for renal P-gp function assessment, a drug 
with lower oral bioavailability such as fexofenadine is recom-
mended for intestinal P-gp function assessment.25 The inhi-
bition of the efflux transporter P-gp by quinidine leads to an 
increase in fexofenadine absorption, hence increasing its AUC 
and Cmax, as observed. The opposite effect is observed in the 
case of P-gp induction by rifampicin, with a twofold decrease 
in AUC and Cmax and an increase in oral clearance. This is 
in agreement with a previously published study in which 
rifampicin and fexofenadine were administered in a stag-
gered manner.37 Full fexofenadine AUC determination can 
be tedious and requires multiple sampling. In this study, we 
have shown that a three-point fexofenadine AUC2,3,6 strongly 
correlated with AUClast and could reliably predict the inter-
action magnitudes. It can thus be used as a limited-sampling 
strategy for P-gp activity assessment after administration of 
25 mg of fexofenadine.
An ideal phenotyping probe is a substrate for a transporter or 
an enzyme which is completely specific. Because currently we do 
not dispose of completely specific probes, it is essential to choose 
probes with a degree of selectivity sufficient to reflect enzyme/
transporter activity in various settings.16 All of the probes 
included in this cocktail, with the exception of flurbiprofen, have 
been listed as sensitive CYP/P-gp substrates by the US Food and 
Drug Administration.38 The validity of these probes/metrics has 
been evaluated in previous studies using different criteria such as 
correlation of the metrics to in vivo expression and activity of the 
proteins, accurate reflection of known genetic polymorphisms, 
or modulation of the metric in the presence of known inhibitors/
inducers.12,16,23,29,30,39,40 The use of metabolic or AUC ratios 
is advantageous, especially for probes having more than one 
metabolizing path, such as omeprazole or dextromethorphan, 
because they give information on the activity of a single CYP 
implicated in one specific pathway. If the metabolite formed is 
further metabolized, i.e., conjugated, one should be aware of the 
effect a modification in conjugating enzyme activities can have 
on the MRs, although the activity of these enzymes is often less 
affected by various disease states or drugs.
In the current study, the main limitation lies in the fact that 
concomitant use of the probe substrates has not been previ-
ously validated. Several cocktail studies have demonstrated the 
lack of interaction between caffeine, omeprazole, dextrometho-
rphan, and midazolam.3,41 We have previously validated the 
use of flurbiprofen with the above-mentioned probes42 and this 
drug has been successfully incorporated into other cocktails.6 
Fexofenadine has been used in combination with some of the 
probes and is not expected to be influenced or to influence 
the pharmacokinetics of the other probes.43,44 A few studies 
have shown that bupropion at steady state (150 mg b.i.d. for 
>2 weeks) can inhibit CYP2D6.45,46 Nevertheless, no evidence 
exists that bupropion would inhibit CYP2D6 when adminis-
tered as a single dose. It is considered that CYP2D6 inhibition 
is mainly mediated by bupropion’s metabolites threohydrobu-
propion and erythrohydrobupropion, which accumulate after 
multiple administrations. The inhibition constant (Ki) values 
for bup, OH-bup, threohydrobupropion, and erythrohydrobu-
propion are 21, 13.3, 5.4, and 1.7 µmol/l, respectively.47 After a 
single 75-mg bupropion dose, the maximal plasma concentra-
tions were 0.49, 0.52, 0.24, and 0.03 µmol/l,  respectively.48 In 
our study, the highest plasma concentrations were observed 
at the inhibition session for bup (Cmax = 0.15 µmol/l) and at 
the induction session for OH-bup (Cmax = 0.35 µmol/l). When 
taking into account the free plasma fraction (0.16–0.58) and a 
liver/plasma ratio of 5.5–9.4,47 the maximal estimated liver con-
centrations for bup, OH-bup, threohydrobupropion, and eryth-
rohydrobupropion would be 0.73, 1.13, 1.31, and 0.16 µmol/l 
after a 75-mg single dose and would be approximately 3 times 
less after a single 25-mg dose (0.24, 0.38, 0.44, and 0.05 µmol/l). 
These concentrations are >10 times lower than the Ki values, 
indicating that a single dose of 25-mg bupropion should not 
have an inhibitory effect on CYP2D6. However, further vali-
dation is necessary to confirm the lack of interactions within 
the cocktail.
After this pilot study, larger population studies should be con-
ducted to evaluate the distribution of CYP and P-gp activities 
and to establish normal activity ranges, allowing the prediction 
of an individual’s phenotype. The clinical utility of phenotyping 
can be evaluated in studies comparing the clinical outcomes 
of phenotype-guided vs. non–phenotype guided therapeutic 
dosing.
In conclusion, this study demonstrated the utility of the DBS-
sampling technique for assessment of the activities of six CYP 
isoforms and P-gp using a low-dose phenotyping cocktail. MRs 
at 2 (CYP1A2 and CYP3A) and 3 h (CYP2B6, CYP2C9, and 
CYP2D6), limited-sampling AUC2,3,6 ratio (CYP2C19), or lim-
ited-sampling AUC2,3,6 (P-gp) can be used as phenotyping met-
rics. These metrics using three DBS samples 2, 3, and 6 h after 
dosing were chosen based on their reliability for predicting both 
normal and altered CYP and P-gp activities. Once validated for 
the lack of interactions, this low-dose, high-throughput cocktail 
method can be applied as a tool in studies of drug–drug interac-
tions or can be used in clinical practice.
METHODS
Subjects. This study (registration NCT01731067) was approved by the 
ethics committee of Geneva University Hospitals (ID: 12–085) and the 
Swiss Agency for Therapeutic Products (Swissmedic).
After giving written informed consent, 10 healthy male volunteers 
were included in the study. Their median age was 23 years (range: 20–36 
years) and median body mass index was 22.0 (range: 19.9–24.4) (see 
 Supplementary Table S1 online for details). One subject was from North 
Africa, one was of mixed Caucasian and African origin, and all the others 
were Caucasians. All of the subjects were nonsmokers and had normal 
results on physical examination, electrocardiogram, and liver function 
test and were not taking any medications. Poor CYP2D6 (*4/*4; *4/*5; 
*5/*5), CYP2C9 (*2/*2; *2/*3; *3/*3), or CYP2C19 (*2/*2) metabolizers 
were not included in the study. Subjects were not permitted to drink 
grapefruit juice for at least 1 week before and throughout the study period 
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and were required to abstain from alcohol and caffeine-containing prod-
ucts at least 48 h before each study session.
Study design. This open-label study was performed in four sessions 
with at least 1-week washout period between each session. Cocktail 
capsules containing low-dose bupropion (25 mg), flurbiprofen (25 mg), 
dextromethorphan (10 mg), omeprazole (5 mg), midazolam (1 mg), 
and fexofenadine (25 mg) were produced by the pharmacy of Geneva 
University Hospitals under good manufacturing practice conditions. At 
each session, after an overnight fast, volunteers received an oral cocktail 
capsule together with a cup of coffee (caffeine: 100 mg) or Coke (caf-
feine: 25 mg). They were given their first meal 1 h after cocktail admin-
istration and a second meal 3 h later. All the volunteers received the 
treatments in the same order. At session 1, volunteers received only the 
cocktail capsule with coffee or Coke. At session 2, volunteers received 
one dose of fluvoxamine (50 mg) 12 h before cocktail administra-
tion, followed by a second dose of fluvoxamine (50 mg) together with 
voriconazole (400 mg) 2 h before cocktail administration (CYP1A2, 
CYP2B6, CYP2C9, CYP2C19, and CYP3A inhibition). At session 3, 
each subject was given 200 mg of quinidine (CYP2D6 and P-gp inhibi-
tor) 2 h before cocktail administration. The CYP and P-gp inhibition 
was divided in two sessions due to the potential interaction (QT interval 
prolongation) between voriconazole and quinidine. Seven days before 
the fourth session, volunteers were given seven tablets of rifampicin 
(600 mg) and were asked to take one tablet every evening until the even-
ing before the session (induction of CYP isoforms and P-gp). They were 
specifically asked about their compliance with the rifampicin regimen.
At each session, capillary and venous blood samples were collected 
simultaneously before and at 0.5, 1, 2, 3, 4, 6, and 8 h after cocktail admin-
istration. Capillary whole blood (10 µl) was collected on a Whatman 
903 filter paper card (Westborough, MA) after a small finger prick (BD 
Microtainer; Contact-Activated Lancet, Plymouth, UK) using a volu-
metric micropipette (Rainin, Oakland, CA), whereas venous blood was 
collected into tubes containing EDTA (BD Vacutainer, Plymouth, UK). 
Plasma from venous blood was obtained after centrifugation at 2,500 rpm 
for 10 min and stored together with dried DBS cards at −20 °C.
Analytical methods. The cocktail substrates and their CYP-specific 
metabolites were quantified in plasma and DBS using a single reverse-
phase high-performance liquid chromatography–tandem mass spec-
trometry method operating in dual electrospray ionization mode, as 
previously described.15 The substances of interest were extracted from 
DBS samples using methanol, whereas protein precipitation using ace-
tonitrile was used for plasma extraction. Both methods (those for DBS 
and plasma) were fully validated according to international criteria.15
Genotyping. Genomic DNA was extracted from whole blood (200 µl) 
using the QIAamp DNA Blood Mini Kit (Qiagen, Switzerland). The 
detection of CYP2C19 (alleles *2 and *3) and 33 CYP2D6 alleles was 
performed using the AmpliChip CYP450 test (Roche Diagnostics, 
Rotkreuz, Switzerland) as previously described.49 CYP2B6*6 and 
CYP2C19*17 genotypes were determined using commercially avail-
able TaqMan SNP genotyping assays. CYP2C9*2 and CYP2C9*3 gen-
otypes, as well as ABCB1 G2677T/A and C3435T polymorphisms, 
were determined by means of multiplex PCR with fluorescent probes 
(Lightmix; TibMolbiol, Berlin, Germany) and melting curve analysis 
on a LightCycler480 (Roche Diagnostics).
Data analysis. Pharmacokinetic parameters were estimated by stand-
ard noncompartmental methods using WinNonlin version 6.2.1 
(Pharsight, Mountain View, CA). The results are presented as mean 
values (± SD) and geometric mean ratios with 95% confidence inter-
vals. Single-point MRs were determined as the concentration ratio 
between the metabolite and the administered substance, i.e., par/caf, 
OH-bup/bup, OH-flb/flb, OH-opz/opz, dor/dem, and OH-mdz/
mdz, at different time points. MRs at the inhibition or induction ses-
sions were compared with those of the cocktail-alone session using a 
nonparametric Wilcoxon signed-rank test. Correlation between AUC 
ratios and single-point MRs was established using Spearman’s rank 
correlation coefficient. All statistical analyses were performed using 
SPSS software version 21 (Chicago, IL). P values ≤ 0.05 were consid-
ered statistically significant.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at 
http://www.nature.com/cpt
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